PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, the

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 6, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement.

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 26, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York , December 3-5, 2019 December 3 , 11:00 a.m.

- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2019 . The company is hosting a conference call at 4:30 p.m.

- Company Expects to Initiate Phase 3 Clinical Trials Next Year PASADENA, Calif. --(BUSINESS WIRE)--Nov. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020 , after a more than 30 year career in biotechnology and pharmaceutical

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019 .

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,